Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Neonatology

Study Questions Effectiveness of Budesonide for Preterm Infants with BPD

A recent study from the Royal Women’s Hospital reveals that combining budesonide with surfactant may not significantly improve survival rates free from bronchopulmonary dysplasia (BPD) in extremely preterm infants. Published in JAMA, the PLUSS trial involved over 1,000 infants and highlights the complexities of treating BPD, a common respiratory condition in preterm babies. Further research is essential to refine treatment protocols and enhance neonatal care.